The ability to detect reduced NPTX2 in cerebrospinal fluid is relevant because targeting parvalbumin interneurons in particular, and circuit defects in general, is emerging as a potential way to treat cognitive impairments in patients with Alzheimer’s disease (Palop and Mucke, 2016). The gene discussed is NPTX2; the disease is Alzheimer disease.